Warifteine is a
bisbenzylisoquinoline alkaloid isolated from the Cissampelos sympodialis Eichl (Menispermaceae). This plant is used in the
folk medicine for the treatment of airway
respiratory diseases. A murine model of immediate
allergic reaction was used to evaluate
warifteine treatment in the
IgE production, leukocyte activation,
thermal hyperalgesia, mast cell degranulation and scratching behavior. BALB/c mice treated with
warifteine (0.4-10 mg/Kg) 1 h before OVA sensitization reduced OVA induced paw
edema as well as the OVA-specific
IgE serum titers as compared with non-treated and OVA-sensitized animals.
Warifteine also reduced the mice death evoked by
IgE-dependent
anaphylactic shock reaction at 30 min after intravenous OVA challenge. To assess the effect of
warifteine treatment on T cell proliferative response, spleen cells from
warifteine treated or non-treated and OVA-sensitized animals were evaluated. Spleen cells from
warifteine treated animals (2.0 mg/kg) did not proliferate following OVA stimulation as compared with spleen cell cultures from non-treated animals. This response may be related with the increase of NO production as observed in peritoneal macrophage cultures treated with
warifteine.
Thermal hyperalgesia evoked by
IgE or
histamine/
5-hydroxytryptamine challenge was inhibited on rats at dose of 4.0 mg/kg.
Warifteine treatment (0.6 or 6.0 microg/ml) also decreased the IgEalphaDNP-BSA sensitized mast degranulation after
DNP-BSA challenge measured by histamine release. In addition,
compound 48/80-induced scratching behavior was also sensitive to
warifteine treatment. These results demonstrate for the first time that
warifteine treatment reduced the
allergy-associated responses.